Stelo by Dexcom: The First Over-the-Counter Glucose Biosensor Now Available in the U.S.
Dexcom, Inc., a leader in continuous glucose monitoring (CGM) technology, has announced the release of Stelo, the first over-the-counter glucose biosensor in the United States.
Stelo is now available for purchase at Stelo.com for adults aged 18 and older who are not using insulin.
Designed specifically for people with type 2 diabetes who are not on insulin and those with prediabetes, Stelo offers 24/7 blood-sugar monitoring without the need for a prescription or fingersticks.
The small, upper-arm biosensor leverages Dexcom’s advanced glucose-sensing technology, providing real-time glucose insights directly to a smartphone. This allows users to understand how food, exercise, and sleep affect their glucose levels, potentially aiding in reaching A1C goals and slowing the progression of diabetes.
“With the launch of Stelo, we’re defining a brand-new category and once again setting the gold standard for people to easily take control of their health,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Now, millions more have access to 24/7, easy-to-understand glucose insights that can inform their daily lifestyle choices and support behavior modification.”
Key features of Stelo include:
- Up to 15 days of wear time
- Waterproof design
- A personalized app that provides daily, weekly, and session summary insights.
Stelo is the only over-the-counter glucose biosensor for people with diabetes that includes spike and pattern detection, allowing users to recognize meaningful glucose variability in real-time.
Priced at $99 for a pack of two sensors, Stelo is also available through a subscription model at $89 per month, which offers a 10% discount.
Stelo is FSA and HSA eligible, making it accessible to more users.
Stelo joins Dexcom’s portfolio of glucose biosensors, including the Dexcom G6 and G7, providing options for people with all types of diabetes and prediabetes.
